KRAS and pancreatic intraductal papillary-mucinous neoplasm: Despite the similar positive prevalence between the KRAS and GNAS mutations (70–80%) in the resected IPMN specimens, a much lower prevalence of KRAS mutation than that of GNAS was detected in cfDNA.